Mercados españoles cerrados

Grifols, S.A. (GRF.MC)

MCE - MCE Precio demorado. Divisa en EUR
Añadir a la lista de favoritos
9,16+0,01 (+0,15%)
Al cierre: 05:35PM CEST

Grifols, S.A.

Avinguda de la Generalitat, 152
Parc empresarial Can Sant Joan Sant Cugat del Valles
Barcelona 08174
Spain
34 935 712 200
https://www.grifols.com

Sector(es)Healthcare
SectorDrug Manufacturers - General
Empleados a tiempo completo23.000

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Thomas H. GlanzmannExecutive Chairman1,9MN/A1958
Mr. Jose Ignacio Abia BuenacheCEO & DirectorN/AN/A1968
Mr. Alfredo Arroyo GuerraCFO & VPN/AN/A1958
Mr. Lluis Pons GomezSenior Vice President of Strategy & COO OfficeN/AN/A1983
Ms. Nuria Pascual LapeñaVP of Corporate Treasury, Risk Management Investor Relation & Sustainability OfficerN/AN/A1964
Mr. David Ian BellChief Corporate Development, Legal & Data Protection OfficerN/AN/A1954
Ms. Maria Teresa-Rioné LlanoChief Communications OfficerN/AN/A1965
Mr. Camille AlpiChief Human Resources & Talent OfficerN/AN/A1981
Mr. Vicente Blanquer TorreChief Quality OfficerN/AN/A1961
Mr. Sergio Roura AdellPresident of Commercial Tech SupportN/AN/A1968
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Gobierno corporativo

El ISS Governance QualityScore de Grifols, S.A., a día 1 de mayo de 2024, es 4. Las puntuaciones base son Auditoría: 2; Tablero: 5; Derechos de los accionistas: 9; Compensación: 4.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.